Per Lofberg wants to bring genomic medicine to the masses by overcoming one of the field’s biggest barriers–getting insurers and other payers to cover the growing numbers of genetic tests reaching the market. To achieve that, he founded Generation Health, a health benefit management company that aims to sift through the data on these tests, which range from those that predict an individual’s risk of heart disease or cancer to those that determine how well a patient metabolizes a certain drug. Lofberg’s goal is to find the ones that provide the greatest medical utility and economic value. Earlier this month, the startup, based in Upper Saddle River, NJ, announced a partnership with CVS Caremark, which manages prescription benefits for about 50 million people. Generation Health will analyze 17 drugs that have accompanying diagnostic tests indicating how well the drug would work in an individual, including those for cancer, heart disease, and HIV, and determine which tests CVS should offer to its customers next year. “Now there is the opportunity to bring genetics to all the people CVS Caremark serves, and that is significant,” says Raju Kucherlapati, a geneticist at Harvard Medical School in Boston. A number of genetic tests can… Read full this story
- The Mobile Healthcare (MHealth) Bible Market Research, Trends And Forecast To Grow Globally By 2020
- Mobile Healthcare (MHealth) Bible Market will account for over 150 Million By 2020
- Next Generation Cancer Diagnostics Market Size To 2022: Grand View Research, Inc.
- Next Generation Cancer Diagnostics Market Size, Segmentation To 2022: Grand View Research, Inc.
Enhancing Access to Genomic Medicine have 266 words, post on www.technologyreview.com at November 23, 2009. This is cached page on wBlogs. If you want remove this page, please contact us.
